MS-27528–31 (HDAC1 selective) and MGCD010332–36 (HDAC1, 2 selective) are two benzamide HDACIs designed for the treatment of both hematologic malignancies and solid cancers, which are currently in clinical trial as mono therapies or in combination with other drugs. This evidence concerns the gene HDAC1 and hematologic disorder.